Modified immunization vectors

Patent metadata

Field	Value
Publication number	US-11345928-B2
Application number	US-201916513757-A
Country	US
Kind code	B2
Filing date	Jul 17, 2019
Priority date	Apr 30, 2009
Publication date	May 31, 2022
Grant date	May 31, 2022

Abstract

The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

First claim

What is claimed is:

1. A recombinant NYVAC vector comprising in its genome at least one polynucleotide encoding:
a) a polypeptide having at least approximately 90% identity to C7L (SEQ ID NO. 17), a polypeptide having at least approximately 90% identity to K1L (SEQ ID NO. 27), and at least one polypeptide having at least approximately 90% identity to a polypeptide selected from the group consisting of C1L (SEQ ID NO. 5), C2L (SEQ ID NO. 7), C3L (SEQ ID NO. 9), C4L (SEQ ID NO. 11), C5L (SEQ ID NO. 13), C6L (SEQ ID NO. 15), N1L (SEQ ID NO. 19), N2L (SEQ ID NO. 21), M1L (SEQ ID NO. 23), and M2L (SEQ ID NO. 25), wherein the at least one polynucleotide encoding the polypeptide having at least approximately 90% identity to C7L (SEQ ID NO. 17) is positioned adjacent to the C8L coding sequence in the genome and the at least one polynucleotide encoding the polypeptide having at least approximately 90% identity to K1L (SEQ ID NO. 27) is positioned adjacent to the K2L coding sequence in the genome; or,
b) a first polypeptide having at least about 90% identity to C7L (SEQ ID NO: 17), and a second polypeptide having at least about 90% identity to K1L (SEQ ID NO: 27), wherein polynucleotides encoding the first polypeptide and second polypeptide are positioned adjacent to one another in the genome.

2. The recombinant NYVAC vector of claim 1 , wherein the identity to C7L and/or K1L is at least approximately 95% or at least approximately 99%.

3. The recombinant NYVAC vector of claim 1 , further comprising a polynucleotide encoding Ambystoma tigrinum virus Eukaryotic Translation Initiation Factor (ATV elF2αH) (SEQ ID NO. 29).

4. The recombinant NYVAC vector of claim 1 , the vector further comprising a polynucleotide encoding an immunogen.

5. The recombinant NYVAC vector of claim 4 , wherein the immunogen directs an immune response against an antigen selected from the group consisting of a viral target antigen, a bacterial target antigen, a parasitic target antigen, or a tumor target antigen.

6. The recombinant NYVAC vector of claim 5 , wherein the viral target antigen is derived from a virus selected from the group consisting of an adenovirus, herpes virus, epstein-barr virus, human cytomegalovirus, varicella-zoster virus, poxvirus, parvovirus, papillomavirus, reovirus, picornavirus, coxsackie virus, hepatitis A virus, poliovirus, togavirus, rubella virus, flavivirus, hepatitis C virus, yellow fever virus, dengue virus, west Nile virus, orthomyxovirus, influenza virus, rhabdovirus, paramyxovirus, measles virus, mumps virus, parainfluenza virus, respiratory syncytial virus, rhabdovirus, rabies virus, retrovirus, human immunodeficiency virus (HIV), hepadnavirus, and hepatitis B virus.

7. The recombinant NYVAC vector of claim 6 , wherein the immunogen is encoded by the genome of HIV-1 intersubtype (C/B 1 ).

8. The recombinant NYVAC vector of claim 6 , wherein the immunogen is selected from the group consisting of Env, Gag, Nef, and Pol.

9. The recombinant NYVAC vector of claim 8 , wherein the immunogen is provided by a GAG-POL-NEF fusion protein.

10. The recombinant NYVAC vector of claim 6 , wherein the immunogen has the amino acid sequence selected from the group consisting of ENV, GAG, POL, NEF, VGNLWVTVYYGVPVW (SEQ ID NO. 56), WVTVYYGVPVWKGAT (SEQ ID NO. 57), GATTTLFCASDAKAY (SEQ ID NO. 58), TTLFCASDAKAYDTE (SEQ ID NO. 59), THACVPADPNPQEMV (SEQ ID NO. 60), ENVTENFNMWKNEMV (SEQ ID NO. 61), ENFNMWKNEMVNQMQ (SEQ ID NO. 62), EMVNQMQEDVISLWD (SEQ ID NO. 63), CVKLTPLCVTLECRN (SEQ ID NO. 64), NCSFNATTVVRDRKQ (SEQ ID NO. 65), NATTVVRDRKQTVYA (SEQ ID NO. 66), VYALFYRLDIVPLTK (SEQ ID NO. 67), FYRLDIVPLTKKNYS (SEQ ID NO. 68), INCNTSAITQACPKV (SEQ ID NO. 69), PKVTFDPIPIHYCTP (SEQ ID NO. 70), FDPIPIHYCTPAGYA (SEQ ID NO. 71), TGDIIGDIRQAHCNI (SEQ ID NO. 72), SSSIITIPCRIKQII (SEQ ID NO. 73), ITIPCRIKQIINMWQ (SEQ ID NO. 74), CRIKQIINMWQEVGR (SEQ ID NO. 75), VGRAMYAPPIKGNIT (SEQ ID NO. 76), MYAPPIKGNITCKSN (SEQ ID NO. 77), PIKGNITCKSNITGL (SEQ ID NO. 78), ETFRPGGGDMRNNWR (SEQ ID NO. 79), ELYKYKVVEIKPLGV (SEQ ID NO. 80), YKVVEIKPLGVAPTT (SEQ ID NO. 81), EIKPLGVAPTTTKRR (SEQ ID NO. 82), LGVAPTTTKRRVVER (SEQ ID NO. 83), and YSENSSEYY (SEQ ID NO. 84).

11. The recombinant NYVAC vector of claim 4 , wherein the bacterial target antigen is derived from a bacterial organism selected from the group consisting of Bacillus anthracis, Bordetella pertussis, Borrelia burgdorferi, Bmeella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diptheriae, Enterococcus faecalis, Enterococcus faecum, Escherichia coli, Francisella tularensis, Haemophilus influenza, Helicobacter pylori, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Neisseria gonorrhea, Neisseria meningitidis, Pseudomonas aeruginosa, Rickettsia rickettsii, Salmonella typhi, Salmonella typhinurium, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus , coagulase negative Staphylococcus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyrogenes, Treponema pallidum, Vibrio cholerae , and Yersinia pestis.

12. The recombinant NYVAC vector of claim 4 , wherein the parasite target antigen is derived from a bacterial organism selected from the group consisting of Ancylostoma duodenale, Anisakis spp., Ascaris lumbricoides, Balantidium coli, Cestoda spp., Cimicidae spp., Clonorchis sinensis, Dicrocoelium dendriticum, Dicrocoelium hospes, Diphyllobothrium latum, Dracunculus spp., Echinococcus granulosus, Echinococcus multilocularis, Entamoeba histolytica, Enterobius vermicularis, Fasciola hepatica, Fasciola magna, Fasciola gigantica, Fasciola jacksoni, Fasciolopsis buski, Giardia lamblia, Gnathostoma spp., Hymenolepis nana, Hymenolepis diminuta, Leishmania spp., Loa boa, Metorchis conjunctus, Metorchis albidus, Necator americanus, Oestroidea spp., Onchocercidae spp., Opisthorchis viverrini, Opisthorchis felineus, Opisthorchis guayaquilensis, Opisthorchis noverca, Plasmodium falciparum, Protofasciola robusta, Parafasciolopsis fasciomorphae, Paragonimus westermani, Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, Schistosoma haematobium, Spirometra erinaceieuropaei, Strongyloides stercoralis, Taenia saginata, Taenia solium, Toxocara canis, Toxocara cati, Toxoplasma gondii, Trichobilharzia regent, Trichinella spiralis, Trichuris trichiura , Trombiculidae spp., Trypanosoma spp., Tungapenetrans, and Wuchereria bancrofti.

13. The recombinant NYVAC vector of claim 4 , wherein the tumor target antigen is selected from the group consisting of: a gp100 (MART-1/Melan A), gp75 (TRP-1), tyrosinase, NY-ESO-1, melanoma proteoglycan, a MAGE family antigen, a BAGE family antigen, a GAGE family antigen, a RAGE family antigens, N-acetylglucosaminyltransferase-V, p15, β-catenin, MUM-1, cyclin dependent kinase-4 (CDK4), p21-ras, BCR-abl, p53, p185 (HER2/neu), epidermal growth factor receptor (EGFR), carcinoembryonic antigen (CEA), a carcinoma-associated mutated mucin, MUC-1, prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), KSA, kinesin 2, HIP-55, TGFβ-1 anti-apoptotic factor, tumor protein D52, H1FT, NY-BR-1, NY-BR-62, NY-BR-75, NY-BR-85, NY-BR-87, NY-BR-96, and a pancreatic cancer antigen.

14. A composition comprising the recombinant NYVAC vector of claim 5 and a pharmaceutically acceptable carrier.

15. A method of inducing an immune

Assignees

• Univ Arizona
• Consejo Superior Investigacion
• Ippox Found
• Conseju Superior De Investig Cientificas

Inventors

• Pantaleo Giuseppe
• Calandra Thierry
• Harari Alexandre
• Roger Thierry
• Esteban Mariano
• Jacobs Bertram
• Kibler Karen
• Melief Cornelius
• Sekaly Rafick-Pierre
• El Haddad Elias
• Tartaglia James

Classifications

• A61K39/295

  Polyvalent viral antigens (vaccinia virus or variola virus A61K39/285); Mixtures of viral and bacterial antigens · CPC title

• A61K2039/5256

  expressing foreign proteins · CPC title

• C12N15/86 Primary

  Viral vectors · CPC title

• C12N2710/24143

  viral genome or elements thereof as genetic vector · CPC title

• A61K39/12

  Viral antigens · CPC title